Could Enrichment Cloud CV Signal For Weight-Loss Drugs?

FDA’s Robert Temple says the trend in risk indicators is the important element when interpreting data from high-risk patients for low-risk patients, after some advisory panel members question the relevance of data from older, sicker participants to the younger patients who take obesity products.

More from Clinical Trials

More from R&D